News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INNOVIVE Pharmaceuticals Presents Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at American Society of Hematology



12/10/2007 11:35:43 AM

ATLANTA--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB: IVPH) today presented clinical data from the first part of a two-part Phase I study of its drug candidate INNO-406, a potent, oral, dual Bcr-Abl and Lyn-kinase inhibitor in patients with Chronic Myelogenous Leukemia (CML). In the study, INNO-406 was shown to be well tolerated and demonstrated activity in patients with CML who are intolerant or resistant to imatinib (GleevecĀ®) and multiple second generation tyrosine kinase inhibitors. The data were presented today at an oral presentation at the 49th American Society of Hematology Annual Meeting in Atlanta.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES